ĐÁNH GIÁ MỨC ĐỘ XƠ HÓA GAN BẰNG FIBROSCAN Ở BỆNH NHÂN MẮC BỆNH GAN NHIỄM MỠ KHÔNG DO RƯỢU TẠI KHOA NỘI TIÊU HÓA BỆNH VIỆN TRUNG ƯƠNG THÁI NGUYÊN NĂM 2025

Abstract

Objective: To assess the degree of liver fibrosis by FibroScan and selected biochemical indices in patients with nonalcoholic fatty liver disease (NAFLD) at the Department of Gastroenterology, Thai Nguyen National Hospital in 2025. Methods: The study included 26 patients diagnosed with alcoholic fatty liver disease at Thai Nguyen National Hospital. The study was conducted from January 2025 to November 2025. Results: The study sample was predominantly middle‑aged adults, with the 40–59 year age group accounting for the largest proportion (38.47%). The male:female ratio was 1:1.36. The proportion of patients with BMI ≥25 kg/m² was 65.38%. Regarding medical history, there were 8 patients who had a history of  smoking (30.76%); dyslipidemia was present in 57.69%; hypertension in 61.54%; and diabetes mellitus in 30.77%. Liver fibrosis measured by FibroScan showed that the majority of patients had mild fibrosis (F0–F1) at 84.62%; clinically significant fibrosis (F2) accounted for 11.53%; advanced fibrosis accounted for 3.85%; and no patients had decompensated fibrosis. Most patients had elevated liver enzymes with mean AST 40.3 U/L, ALT 63.3 U/L, and GGT 58.6 U/L. In addition, hypertriglyceridemia was present in 73.09%; hypercholesterolemia in 46.15%; elevated LDL in 46.15%; and low HDL in 15,38%. Conclusion: The study demonstrates the risk factors and disease pattern consistent with nonalcoholic fatty liver disease. A notable proportion of patients exhibit progressive hepatic fibrosis and therefore require close follow up.